Ethnicity, genomic ancestry, and HBV genotype in off-treatment outcomes following nucleos(t)ide analogue cessation: a prospective multicentre trial (COIN-B)
Open Access
- 8 October 2026
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Abstract
Nucleos(t)ide analogue (NUC) cessation can induce functional cure, but outcomes vary. Ethnicity has been suggested as a determinant, but definitions are subjective and inconsistent. In this prospective, multicentre trial (NCT04779970, EudraCT 2021-001003-32), 91 long-term NUC-treated, start-of-treatment HBeAg-negative patients without advanced fibrosis discontinued treatment; 84 completed the 72-week protocol. In the prespecified analysis, off-treatment viral control at week 72 (primary endpoint) did not differ between Caucasians (n = 41) and non-Caucasians (n = 43) (41.5% vs 30.2%, p = 0.28). In exploratory analyses, HBsAg loss (7.1%, secondary endpoint) occurred exclusively in European or North African/Middle Eastern genomic ancestries, and ≥1 log IU/mL HBsAg decline was less frequent in Asian or Sub-Saharan African ancestries (p = 0.01). Lower end-of-treatment HBsAg independently predicted viral control, HBsAg loss and decline. Adjusted for end-of-treatment HBsAg, genotypes C and D achieved less viral control and required more retreatment than genotype A. Here, we show that genomic ancestry and HBV genotype capture clinically relevant heterogeneity, calling for more granular characterization of eligible populations. Clinical trial information EudraCT: 2021-001003-32. Date of registration: 7 June 2021 CTIS: 2024-511016-25-00. Date of transition from EudraCT: 15 January 2025 Clinicaltrials.gov: NCT04779970. Date of registration: 28 July 2021.Keywords
Funding Information
- Fonds Wetenschappelijk Onderzoek (T002920N)
- Fonds Wetenschappelijk Onderzoek (18B2826N)
This publication has 51 references indexed in Scilit:
- Abandoning the word CaucasianJournal of Genetic Counseling, 2023
- High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 triosCell, 2022
- Clinical management of chronic hepatitis B: A concise overviewUnited European Gastroenterology Journal, 2021
- HBV Genotype: A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC: The Hepatitis B Alaska StudyHepatology, 2021
- Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science JournalsJAMA, 2021
- Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV GenotypesHepatology, 2021
- Pregenomic HBV RNA and Hepatitis B Core‐Related Antigen Predict Outcomes in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue TherapyHepatology, 2019
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis BHepatology, 2017
- Different Hepatitis B Virus Genotypes Are Associated With Different Mutations in the Core Promoter and Precore Regions During Hepatitis B E Antigen SeroconversionHepatology, 1999